Development of an Orally Available and Central Nervous System (CNS)-Penetrant Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-à-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis

New therapies are needed for the treatment of toxoplasmosis, which is a disease caused by the protozoan parasite Toxoplasma gondii. To this end, we previously developed a potent and selective inhibitor (compound 1) of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) that possesses anti...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Med Chem
Autori principali: Vidadala, Rama Subba Rao, Rivas, Kasey L., Ojo, Kayode K., Hulverson, Matthew A., Zambriski, Jennifer A., Bruzual, Igor, Schultz, Tracey L., Huang, Wenlin, Zhang, Zhongsheng, Scheele, Suzanne, DeRocher, Amy E., Choi, Ryan, Barrett, Lynn K., Siddaramaiah, Latha Kallur, Hol, Wim G. J., Fan, Erkang, Merritt, Ethan A., Parsons, Marilyn, Freiberg, Gail, Marsh, Kennan, Kempf, Dale, Carruthers, Vern B., Isoherranen, Nina, Doggett, J. Stone, Van Voorhis, Wesley C., Maly, Dustin J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5100899/
https://ncbi.nlm.nih.gov/pubmed/27309760
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.6b00760
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi